JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

A retrospective analysis of the clinicopathological features and prognostic value of MAPK12 protein expression in diffuse large B-cell lymphoma

  • 0Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico +

|

May 21, 2024

|

May 21, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

High levels of Mitogen-activated protein kinase 12 (MAPK12) correlate with poor prognosis in diffuse large B-cell lymphoma (DLBCL) patients. MAPK12 is identified as a potential therapeutic target and prognostic factor for DLBCL.

Area Of Science

  • Oncology
  • Molecular Biology
  • Immunology

Background

  • Mitogen-activated protein kinase 12 (MAPK12), also known as p38γ, is implicated in tumor development and invasion.
  • The specific role of MAPK12 in diffuse large B-cell lymphoma (DLBCL) remains unclear.

Purpose Of The Study

  • To investigate the expression and prognostic significance of MAPK12 in DLBCL.
  • To explore the functional role of MAPK12 in DLBCL pathogenesis.

Main Methods

  • Bioinformatic analysis of MAPK12 mRNA expression across various cancers.
  • Immunohistochemistry (IHC) to assess MAPK12 protein levels in DLBCL patient samples.
  • Weighted gene co-expression network analysis (WGCNA) and Gene Ontology (GO) for functional pathway exploration.

Main Results

  • MAPK12 was highly expressed in 43.1% of DLBCL patients.
  • High MAPK12 expression was associated with clinical indicators like IPI scores, Hans classifications, LDH, and Ki-67 levels.
  • Elevated MAPK12 expression correlated significantly with shorter progression-free survival (PFS) and overall survival (OS) in DLBCL patients.
  • IPI score, MAPK12 expression, and rituximab use were identified as independent OS risk factors.
  • Functional analysis suggested MAPK12 involvement in type II interferon production and lymphocyte proliferation.

Conclusions

  • High MAPK12 expression is linked to poor prognosis in DLBCL.
  • MAPK12 is a potential prognostic factor and therapeutic target for DLBCL.

Keywords: